Frodo wrote:According to German „Planet Wissen“, in about 1,5 hours a person‘s entire blood flows once through the thyroid gland. It is thus four to five times more strongly supplied with blood than the kidneys. And indeed others say, every 17 minutes. Blood supply through arteria thyroidea superior from the arteria carotis externa and through arteria thyroidea inferior.
Frodo wrote:Another interesting article by Riordan Clinic: „The Miracle Molecule“.
Since years I stimulate my body‘s own NO production with 6 g L-arginine and 2 g L-citrulline. According to the recommendation of nobel prize winner Louis Ignarro (I recommend his book „NO More Heart Disease“). Supplemented by other necessary vital substances. It „cured“ my high blood pressure. It is now even mostly below the norm 120/80. Without the helpless and harmful pharmaceutical drugs.
Next week I‘ll check my lp(a) level again. I want to know if niacin has effects. I increased niacin to 2 g and endure the flush
My last value was 175 nmol.
Code: Select all
year Lp(a) mg_Kyolic
2009 57 200
2010 47 690
2011 59 870
2012 55 830
2013 43 790
2014 47 420
2015 35 180
2016 51 620
2017 45 820
2018 58 1140
Frodo wrote:This does not correspond to the Pauling/Rath therapy.
SUMMARY OF THE INVENTION
The foregoing needs in the treatment and prevention of cardiovascular disease are met by the methods and compositions of the present invention.
A method is provided for the treatment of occlusive cardiovascular disease, comprising the step of administering to a subject an effective amount of ascorbate and one or more binding inhibitors, as a mixture or as a compound comprising ascorbate covalently linked with binding inhibitors, which inhibit the binding of Lp(a) to blood vessel walls, such as arterial walls. This effect may also be obtained by administering an effective amount of one or more inhibitors, without ascorbate. The term binding inhibitor throughout the specification and claims is intended to include all substances that have an affinity for the lysine binding site present on the interior walls of blood vessels, particularly arteries, the site of Lp(a) binding. Most of these substances compete with plasmin for the lysine binding site and some of these compounds, in high doses, are in clinical use for the treatment of hyperfibrinolytic states.
Users browsing this forum: No registered users and 9 guests